Cardio Diagnostics Unveils Molecular Test to Address Blind Spots in Coronary Heart Disease Detection

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is bringing molecular precision to a longstanding blind spot in coronary heart disease (CHD) detection, as approximately 50% of individuals with CHD do not present with traditional risk factors, according to the company. Conventional risk calculators have an average sensitivity of just 39%, meaning many patients who appear healthy may still be at risk of preventable cardiac events such as heart attacks.

For decades, cardiovascular risk assessment has relied on a checklist of factors including cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors are useful, they were never designed to capture the full biological picture of how heart disease develops. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics that examine how genes are expressed and regulated at the molecular level, aiming to detect CHD earlier and more accurately.

Coronary heart disease remains the leading cause of death in the United States, yet the tools doctors have long relied on are proving less reliable than many patients assume. The company’s approach could transform screening by identifying molecular markers of disease before symptoms appear, potentially reducing the number of unexpected cardiac events. This is particularly important given that a significant portion of CHD is preventable with early intervention.

Cardio Diagnostics’ tests are designed to complement existing risk assessments, providing a more comprehensive view of a patient’s cardiovascular health. By incorporating epigenetic and genetic analysis, the tests can reveal risks that traditional methods miss. The company notes that its technology addresses a critical gap in current clinical practice, where many patients are falsely reassured by normal cholesterol and blood pressure readings.

The implications of this announcement are significant for public health. If widely adopted, molecular precision testing could shift the paradigm from reactive care to proactive prevention. For investors, the development highlights the growing role of precision medicine in cardiology. More information about Cardio Diagnostics is available at their newsroom at https://ibn.fm/CDIO.

BioMedWire, the source of this press release, is a communications platform focused on biotechnology and life sciences sectors. It is part of the Dynamic Brand Portfolio @IBN, which provides wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications services. For more details, visit https://www.BioMedWire.com.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Cardio Diagnostics Unveils Molecular Test to Address Blind Spots in Coronary Heart Disease Detection.

The post Cardio Diagnostics Unveils Molecular Test to Address Blind Spots in Coronary Heart Disease Detection appeared first on citybuzz.